Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Nutrients. 2022 Jul 9;14(14):2831. doi: 10.3390/nu14142831.


This study was aimed at assessing the efficacy and safety of inositol nutritional supplementation during pregnancy for the prevention of GDM. PubMed, Embase, MEDLINE, and Cochrane library were systematically searched for randomized controlled trails (RCTs) in this field until May 2022. Primary outcomes were the incidence for GDM and plasma glucose levels by oral glucose tolerance test (OGTT). Pooled results were expressed as relative risk (RR) or mean difference (MD) with a 95% confidence interval (95% CI). Seven RCTs with 1321 participants were included in this study. Compared with the control group, 4 g myo-inositol (MI) supplementation per day significantly decreased the incidence of GDM (RR = 0.30, 95% CI (0.18, 0.49), p < 0.00001). It significantly decreased the plasma glucose levels of OGTT regarding fasting-glucose OGTT (MD = −4.20, 95% CI (−5.87, −2.54), p < 0.00001), 1-h OGTT (MD = −8.75, 95% CI (−12.42, −5.08), p < 0.00001), and 2-h OGTT (MD = −8.59, 95% CI (−11.81, −5.83), p < 0.00001). It also decreased the need of insulin treatment, and reduced the incidence of preterm delivery and neonatal hypoglycemia. However, no difference was observed between 1.1 g MI per day plus 27.6 mg D-chiro-inositol (DCI) per day and the control group regarding all evaluated results. In conclusion, 4 g MI nutritional supplementation per day during early pregnancy may reduce GDM incidence and severity, therefore may be a practical and safe approach for the prevention of GDM.

Keywords: D-chiro-inositol; gestational diabetes mellitus; inositol; insulin resistance; meta-analysis; myo-inositol; randomized controlled trial.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Blood Glucose
  • Diabetes, Gestational* / epidemiology
  • Diabetes, Gestational* / prevention & control
  • Dietary Supplements
  • Female
  • Humans
  • Infant, Newborn
  • Inositol* / therapeutic use
  • Pregnancy
  • Randomized Controlled Trials as Topic


  • Blood Glucose
  • Inositol

Grants and funding

This research was funded by the National Key Research and Development Program of China (No. 2021YFC2700700) and Peking University First Hospital Medicine Fund of Fostering Young Scholars under grant (No. 2021CR01).